NCT03884101 2026-02-02
LEAP-001
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
27 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT02730416 2025-07-29
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT03517449 2025-06-15
MK-3475-775
Eisai Inc.
Phase 3 Completed
NCT03603184 2025-05-09
AtTEnd
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT00513786 2025-03-28
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02630823 2025-01-03
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
Phase 1 Completed
NCT03189446 2024-03-08
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
University of Oklahoma
Phase 2 Completed
NCT03366480 2023-02-22
Endolung
Ability Pharmaceuticals SL
Phase 1/2 Completed
NCT02788708 2022-09-19
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02549209 2022-03-02
Pembro/Carbo/Taxol in Endometrial Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02725268 2021-11-24
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Takeda
Phase 2 Completed
NCT02269293 2021-04-23
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00006027 2020-10-22
Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01256268 2017-08-30
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00879359 2017-04-26
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00502203 2016-05-09
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00515073 2014-07-03
Papillary Serous Carcinoma of the Endometrium
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00408655 2014-06-19
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002949 2013-09-05
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
University of Chicago
Phase 1 Completed
NCT00006377 2013-06-18
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00028535 2013-06-04
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00756847 2013-04-10
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
Sanofi
Phase 1 Completed
NCT00022620 2012-09-24
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00052312 2012-09-24
Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00003127 2012-06-14
S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer
SWOG Cancer Research Network
Phase 2 Completed